Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma
Pediatric Blood & Cancer2020Vol. 67(6), pp. e28267–e28267
Citations Over TimeTop 12% of 2020 papers
Jason Healy, Lori S. Hart, Alexander L. Shazad, Maria Gagliardi, Matthew Tsang, Jimmy Elias, Jacob B. Ruden, Alvin Farrel, Jo Lynne Rokita, Yimei Li, Anastasia Wyce, Olena Barbash, Vandana Batra, Minu Samanta, John M. Maris, Robert W. Schnepp
Abstract
Combinatorial BET and MEK inhibition was synergistic in the vast majority of neuroblastoma cell lines in the in vitro setting but showed limited antitumor activity in vivo. Collectively, these data do not support clinical development of this combination in high-risk neuroblastoma.
Related Papers
- → Frequent detection of human cytomegalovirus in neuroblastoma: A novel therapeutic target?(2013)74 cited
- → Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma(2013)29 cited
- → Abstract 781: The tumor suppressive microRNA-15 family targets MYCN in neuroblastoma(2019)1 cited
- → Abstract 356: Role of the LMO1 oncogene in neuroblastoma pathogenesis.(2013)
- → Supplementary figures from Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition(2023)